Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...
Munich (ots/PRNewswire) - - Recommended label update for LIXIANA® provides guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion - Update is based on data from ENSURE-AF, the largest prospective randomised clinical trial of anticoagulation for ...
Munich (ots/PRNewswire) - - ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) ...
5GAA - 5G Automotive Association e.V.
Munich (ots) - The 5G Automotive Association (5GAA) submitted comments to the National Highway Traffic Safety Administration (NHTSA) notice of proposed rulemaking (NPRM), "Federal Motor Vehicle Safety Standards; V2V Communications." The proposed rule is to mandate new light-duty vehicles to be equipped with dedicated short range communications (DSRC). 5GAA is a new ...
Munich (ots/PRNewswire) - - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled ...
Munich (ots/PRNewswire) - First patient enrolled in EMIT-AF/VTE study (NCT02950168), a European registry to assess edoxaban management in patients undergoing medical procedures[1] Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the first patient has been enrolled in the EMIT-AF/VTE ...
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
Munich (ots/PRNewswire) - - Four abstracts highlight new subgroup analyses from the global phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies to be presented in oral and poster sessions Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today announced that data from three new subgroup analyses from the ...
Munich (ots/PRNewswire) - Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss - G-BA), has granted an indication of a minor additional benefit for LIXIANA® (edoxaban), an oral, once-daily selective ...
Munich (ots/PRNewswire) - - On World Stroke Day (29 October) a campaign by Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases - People with atrial fibrillation have a five times higher stroke risk compared to the general population.[1] In Europe less than 50% of patients with ...
Munich (ots/PRNewswire) - World Thrombosis Day Interactive Infographic [http://af-vte.thisinfographic.com/wtd ] Daiichi Sankyo is proud to partner with World Thrombosis Day [http://www.worldthrombosisday.org ] to promote vital global awareness of thrombosis, its causes, risk factors, and signs and symptoms. ...
Munich (ots/PRNewswire) - FOR EU MEDIA ONLY. NOT FOR UK MEDIA. - Daiichi Sankyo announces enrollment of first patient in ETNA-AF-Europe and the commencement of ETNA-VTE-Europe, two regional registries to collect robust information on how once-daily LIXIANA(R) is being used in real world settings - ETNA is a Daiichi Sankyo global initiative which will collect data ...
Munich (ots) - Introduction of new "Elements" completes the portfolio of automated, indication-specific planning tools for radiosurgery/SBRT The "Elements" strategy-indication-specific focused software applications aimed at enhancing the workflow for difficult to treat indications in the brain and spine introduced in 2013-comes full circle with the introduction of ...
Munich (ots/PRNewswire) - - Survey findings show that 97% of European cardiologists believe that non-valvular atrial fibrillation (NVAF) patients experience a delay in diagnosis,[1] which is associated with a higher risk of stroke[2] - European Cardiologists reveal the importance of reviewing patient ...
Montreal/Munich (ots) - Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest ...
Munich (ots) - - Voluntary public tender offer expired - all offer conditions have been met - Circa 74.70 per cent of the outstanding preference shares of WMF have been tendered - Together with shares acquired outside the offer and in combination with shares held by FIBA, a shareholding quota of circa 90.30 per cent is reached - Squeeze-out of the remaining shareholders of WMF AG planned Finedining Capital GmbH ...
Medical Device UDIs & Traceability Forum
Munich (ots/PRNewswire) - **Ensure compliance with the new FDA and European Rules on Unique Device Identifiers** The FDA released the Final Rule on Unique Device Identifiers (UDIs) for all medical devices being sold or shipped into the US, and companion guidelines from the European Commission are due soon for Europe. In light of this, Healthcare IQ would like to stress ...